Pamela N. Munster

Pamela N. Munster

Auto-generated profile, based on publicly available information

Pamela N. Munster

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PMP N Munster
P N Munster
KTK T Thurn
K T Thurn
STS Thomas
S Thomas
PRP Raha
P Raha
MLM Lacevic
M Lacevic
SMS E Minton
S E Minton
Background: Methods: Results: Conclusion:

19 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AFAnniina Färkkilä
Anniina Färkkilä
DGDoga C. Gulhan
Doga C. Gulhan
JCJulia Casado
Julia Casado
CJConnor A. Jacobson
Connor A. Jacobson
HNHuy Nguyen
Huy Nguyen
PKPanagiotis A. Konstantinopoulos
Panagiotis A. Konstantinopoulos
Combined PARP and immune checkpoint inhibition has yielded encouraging results in ovarian cancer, but predictive biomarkers are lacking. We performed immunogenomic profiling and highly multiplexed single-cell imaging on tumor samples from patients enrolled in a Phase I/II trial of niraparib and pembrolizumab in ovarian cancer (NCT02657889). We identify two determinants of response; mutational signature 3 reflecting defective homologous recombination DNA repair, and positive immune score as a surrogate of interferon-primed exhausted CD8 + T-cells in the tumor microenvironment. Presence of one or both features associates with an improved outcome while concurrent absence yields no responses. Single-cell spatial analysis reveals prominent interactions of exhausted CD8 + T-cells and PD-L1 + macrophages and PD-L1 + tumor cells as mechanistic determinants of response. Furthermore, spatial analysis of two extreme responders shows differential clustering of exhausted CD8 + T-cells with PD-L1 + macrophages in the first, and exhausted CD8 + T-cells with cancer cells harboring genomic PD-L1 and PD-L2 amplification in the second.

23 February 2011 in Future Oncology
Verified
Journal Article
Closed access
KTK Ted Thurn
K Ted Thurn
STScott Thomas
Scott Thomas
AMAmy Moore
Amy Moore
PMPamela N Munster
Pamela N Munster
Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and nonhistone proteins, controlling the transcription and regulation of genes involved in cell cycle control, prolifer...

10 February 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PMPamela N. Munster
Pamela N. Munster
AMAmy P. Moore
Amy P. Moore
Roohi Ismail-KhanRoohi Ismail-Khan
Roohi Ismail-Khan
CCCharles E. Cox
Charles E. Cox
MLMensura Lacevic
Mensura Lacevic
SMSusan E. Minton
Susan E. Minton
Purpose: Chemotherapy-induced amenorrhea is a serious concern for women undergoing cancer therapy. This prospective randomized trial evaluated the use of gonadotropin-releasing hormone (GnRH) analog triptorelin to preserve ovarian function in women treated with chemotherapy for early-stage breast cancer. Patients and Methods: Premenopausal women age 44 years or younger were randomly assigned to receive either triptorelin or no triptorelin during (neo)adjuvant chemotherapy and were further stratified by age (< 35, 35 to 39, > 39 years), estrogen receptor status, and chemotherapy regimen. Objectives included the resumption of menses and serial monitoring of follicle-stimulating hormone (FSH) and inhibin A and B levels. Results: Targeted for 124 patients with a planned 5-year follow-up, the trial was stopped for futility after 49 patients were enrolled (median age, 39 years; range, 21 to 43 years); 47 patients were treated according to assigned groups with four cycles of adriamycin plus cyclophosphamide alone or followed by four cycles of paclitaxel or six cycles of fluorouracil, epirubicin, and cyclophosphamide. Menstruation resumed in 19 (90%) of 21 patients in the control group and in 23 (88%) of 26 in the triptorelin group (P= .36). Menses returned after a median of 5.8 months (range, 1 to 19 months) after completion of chemotherapy in the triptorelin versus 5.0 months (range, 0 to 28 months) in the control arm (P= .58). Two patients (age 26 and 35 years at random assignment) in the control group had spontaneous pregnancies with term deliveries. FSH and inhibin B levels correlated with menstrual status. Conclusion: When stratified for age, estrogen receptor status, and treatment regimen, amenorrhea rates on triptorelin were comparable to those seen in the control group.

15 March 2012 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
NLNancy U.T. Lin
Nancy U.T. Lin
EWEric P. Winer
Eric P. Winer
DWDuncan Wheatley
Duncan Wheatley
LCLisa A. Anne Carey
Lisa A. Anne Carey
SHStephen Houston
Stephen Houston
THTamas Hickish
Tamas Hickish
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing after trastuzumab treatment. Patients had stage IIIB/IV HER2-positive metastatic breast cancer, with progression following trastuzumab or trastuzumab intolerance and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Patients received 50 mg afatinib once-daily until disease progression. Primary endpoint was objective response rate (Response Evaluation Criteria in Solid Tumors 1.0), with tumor assessments every 8 weeks. Forty-one patients were treated. Patients had received a median of three prior chemotherapy lines (range, 0–15) and 68.3% had received trastuzumab for >1 year. Four patients (10% of 41 treated; 11% of evaluable patients) had partial response. Fifteen patients (37% of 41) had stable disease as best response and 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks (95% confidence interval [CI]: 8.1–16.7); median overall survival was 61.0 weeks (95% CI: 56.7–not evaluable). Most frequent common terminology criteria for adverse events grade 3 treatment-related adverse events were diarrhea (24.4%) and rash (9.8%). Afatinib monotherapy was associated with promising clinical activity in extensively pretreated HER2-positive breast cancer patients who had progressed following trastuzumab treatment.

12 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MTManuela Terranova-Barberio
Manuela Terranova-Barberio
STScott Thomas
Scott Thomas
NANiwa Ali
Niwa Ali
NPNela Pawlowska
Nela Pawlowska
JPJeenah Park
Jeenah Park
PMPamela N. Munster
Pamela N. Munster
HDAC inhibition potentiates immunotherapy in triple negative breast cancer HDAC inhibition potentiates immunotherapy in triple negative breast cancer